Working... Menu

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00925132
Recruitment Status : Terminated (Change in the number of approved drugs for metastatic melanoma)
First Posted : June 19, 2009
Results First Posted : July 2, 2017
Last Update Posted : July 2, 2017
Holden Comprehensive Cancer Center
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Mohammed M Milhem, University of Iowa

Brief Summary:

The purpose of this study is to treat metastatic melanoma with a combination of standard chemotherapy (decitabine and Temozolomide in a dose escalation scheme) with an study drug called panobinostat. This combination is proposed to unlock genes that may contribute to mechanisms that cause tumor growth.

The primary objectives of this study are:

  • To evaluate the safety and tolerability of the proposed schedule of decitabine, temozolomide and panobinostat in the treatment of metastatic melanoma.
  • To define any Dose Limiting Toxicity (DLT) and maximum tolerated dose (MTD) of the combination of decitabine, temozolomide and panobinostat.

Condition or disease Intervention/treatment Phase
Metastatic Melanoma Drug: Temozolomide, Decitabine, Panobinostat Phase 1 Phase 2

Detailed Description:

Most chemotherapeutics target rapidly proliferating cells, leaving quiescent cells and those with extended cell cycles unaffected. The investigators propose that this combination of decitabine, temozolomide, and panobinostat will target both melanoma stem cells and rapidly proliferating melanoma cells. The use of two drugs that regulate gene expression epigenetically (panobinostat and decitabine) in combination with a chemotherapeutic agent (temozolomide) is hypothesized to:

  • induce expression genes (e.g., Apaf-1) that increase chemosensitivity of tumor cells and enhance apoptosis
  • potentiate the cytotoxic effect of temozolomide by epigenetic modulation, and
  • induce proliferation and differentiation of tumor stem cells, thus enabling senescence and apoptosis.

Secondary objectives:

  • To measure overall survival
  • To measure the time to progression of patients treated with this combination in comparison to patients treated historically with DTIC (the current standard of care).
  • To evaluate treatment response with FDG PET and compare FDG PET with conventional imaging for treatment response assessment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ib/II: Epigenetic Modification of Chemosensitivity and Apoptosis in Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine, Temozolomide and Panobinostat
Actual Study Start Date : December 2009
Actual Primary Completion Date : November 2014
Actual Study Completion Date : December 2016

Arm Intervention/treatment
Experimental: Temozolomide, Decitabine, Panobinostat

Temozolomide - given each cycle.

Decitabine - 6 cohorts with dose escalation.

Panobinostat - 6 cohorts with dose escalation.

Drug: Temozolomide, Decitabine, Panobinostat

Temozolomide - given each cycle.

Decitabine - 6 cohorts with dose escalation.

Panobinostat - 6 cohorts with dose escalation.

Other Name: LBH589

Primary Outcome Measures :
  1. Phase I - Number of Participants With Dose Limiting Toxicities (DLTs) at a Given Dose Level [ Time Frame: 6 weeks (one full cycle) ]

    A DLT was any Grade 4 toxicity for neutrophils or platelets for ≥ 7 days, Grade 3 toxicity for neutrophils for ≥ 21 days, any Grade 3 solid organ toxicity not explainable by another cause (e.g. neurotoxicity, GI toxicity), metabolic/laboratory toxicity (≥10 x ULN AST) for ≥ 14 days, any Grade 4 infection or QTcF> 500msec EKG. DLTs were assessed according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0.

    All adverse events were collected and graded to determine DLTs as assessed according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0. DLTs were assessed to determine the recommended Decitabine and Panobinostat dose for the Phase II portion of the trial.

  2. Phase 2 -Number of Patients With a Decrease in Tumor Size Using RECIST and CHOI's Criteria [ Time Frame: 12 weeks (2 cycles) ]

    Tumor response rate was assessed using RECIST criteria in which a complete response was the disappearance of all target lesions; Partial response was a 30% decrease in the sum of the longest dimension (LD) of target lesions, relative to baseline measurement; Progressive disease was an increase of 20% or more in the sum of the LD of target lesions; and Stable disease was a decrease in tumor size of less than 30% or increase of less than 20%.

    Tumor response rate was also assessed using CHOI's criteria in which a response was a 10% decrease in tumor size or a 15% decrease in tumor density on contrast-enhanced computed tomography scan.

    Tumor response rates were assessed in order to determine effectiveness of the treatment regimen which was defined by the response rate of at least 30% as measured by either the RECIST or Choi's criteria, and ineffective if the rate is less than 15% on both.

Secondary Outcome Measures :
  1. Phase 2 - Number of Participants With Disease Progression [ Time Frame: 5 years ]
    Number of participants who died or had disease progression

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patients aged ≥ 18 years old
  2. ECOG Performance Status of ≤ 2
  3. Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
  4. Patients must have measurable disease according to RECIST and CHOI criteria. The minimum target-lesion diameter should have double the CT slice thickness, i.e., 10 mm
  5. Patients must meet the following laboratory criteria:

    Hematology: Neutrophil count of >1500/mm3;Platelet count of > 100,000/mm3L; Hemoglobin ≥ 9 g/dL Biochemistry:AST/SGOT and ALT/SGPT ≤ 2.5 x upper limit of normal (ULN) or ≤ 5.0 x upper limit of normal if the transaminase elevation is due to disease involvement;Serum bilirubin ≤ 1.5 x upper limit of normal;Serum creatinine ≤ 1.5 x upper limit of normal or 24-hour creatinine clearance ≥ 50 ml/min; Total serum calcium (corrected for serum albumin) or ionized calcium ≥ lower limit of normal; Serum potassium ≥ lower limit of normal; Serum sodium ≥ lower limit of normal;Serum albumin ≥ lower limit of normal or 3g/dl;Patients with any elevated alkaline phosphatase due to bone metastasis can be enrolled

  6. Baseline ECHO must demonstrate LVEF ≥ the lower limit of the institutional normal.
  7. TSH and free T4 within normal limits (patients may be on thyroid hormone replacement)
  8. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 8 days of the first administration of study treatment and must be willing to use two methods of contraception one of them being a barrier method during the study and for 3 months after last study drug administration
  9. Any patient with the diagnosis of metastatic melanoma from any site. These include untreated patients or those treated with chemotherapy or biochemotherapy.
  10. Must not have taken a hypomethylating agent or a histone deacetylase agent in the treatment of their disease. Patients who receive targeted agents would only need a 2-week washout period.
  11. Any patient with metastatic melanoma regardless of prior treatment will be eligible.
  12. Patients must have had disease progression on or following their most recent treatment regimen or on presentation for the first time with metastatic disease, surgical option can be entertained if this is a localized relapse.
  13. Patients with CNS disease are eligible for treatment only after their CNS disease has been directly addressed with radiation therapy.

Exclusion Criteria:

  1. Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer
  2. Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatment
  3. Impaired cardiac function including any one of the following: Screening ECG with a QTc > 450 msec confirmed by central laboratory prior to enrollment to the study; Patients with congenital long QT syndrome; History of sustained ventricular tachycardia; Any history of ventricular fibrillation or torsades de pointes; Bradycardia defined as heart rate < 50 beats per minute. Patients with a pacemaker and heart rate ≥ 50 beats per minute are eligible; Patients with a myocardial infarction or unstable angina within 6 months of study entry; Congestive heart failure (NY Heart Association class III or IV);Right bundle branch block and left anterior hemiblock (bifascicular block)
  4. Uncontrolled hypertension
  5. Concomitant use of drugs with a risk of causing torsades de pointes
  6. Concomitant use of CYP3A4 inhibitors
  7. Patients with unresolved diarrhea > CTCAE grade 1
  8. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral panobinostat
  9. Other concurrent severe and/or uncontrolled medical conditions
  10. Patients who have received chemotherapy, any investigational drug or undergone major surgery < 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
  11. Concomitant use of any anti-cancer therapy or radiation therapy.
  12. Patients who have no measurable disease.
  13. Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)not willing to use a double barrier method of contraception during the study and 3 months after the end of treatment. One of these methods of contraception must be a barrier method. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months(i.e., who has had menses any time in the preceding 12 consecutive months). Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 8 days of the first administration of oral panobinostat.
  14. Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and 3 months after the end of treatment. One of these methods must be a condom
  15. Patients with a history of another primary malignancy within 5 years other than curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin
  16. Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
  17. Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00925132

Layout table for location information
United States, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242
Sponsors and Collaborators
University of Iowa
Holden Comprehensive Cancer Center
Novartis Pharmaceuticals
Layout table for investigator information
Principal Investigator: Mohammed Milhem, MD University of Iowa

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Mohammed M Milhem, Clinical Associate Professor, University of Iowa Identifier: NCT00925132     History of Changes
Other Study ID Numbers: 200807728
First Posted: June 19, 2009    Key Record Dates
Results First Posted: July 2, 2017
Last Update Posted: July 2, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Mohammed M Milhem, University of Iowa:

Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antimetabolites, Antineoplastic
Enzyme Inhibitors
Histone Deacetylase Inhibitors